3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
30
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
4
Neoplasm Metastasis
3
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Recurrence
1
Prostatic Diseases
1
Patient Preference
1
Metastatic Castration-resistent Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
MCRPC
1
Genital Diseases, Male
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
radium Ra 223 dichloride
1
niraparib
1
enzalutamide
1
darolutamide
1
capivasertib
1
cabazitaxel
1
apalutamide
1
abiraterone
1
Solutions
1
Prednisone
1
Injections
1
Docetaxel
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
enzalutamide
×
Clear all
NCT03903835
2025-04-09
ProBio
Karolinska Institutet
Phase 3
Recruiting
750 enrolled